PAVmed Inc. Annual report pursuant to Section 13 and 15(d)

Stock-Based Compensation - Schedule of Unrecognised Compensation Expense (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 1,570,652	$ 1,228,699
Research and Development Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	408,282	280,556
2018 Long-Term Incentive Equity Plan [Member] \| Lucid Diagnostics Inc [Member] \| Employees and Non-employees [Member] \| Research and Development Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	158,123	40,748
2014 Long Term Incentive Equity Plan [Member] \| Lucid Diagnostics Inc [Member] \| Employees and Non-employees [Member] \| Research and Development Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	15,822	12,485
2018 Long Term Incentive Equity Plan [Member] \| Lucid Diagnostics Inc [Member] \| Research and Development Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 173,945	$ 53,233